I headed out to Las Vegas, Nevada to attend the Vascular InterVentional Advances (VIVA) conference, an important event that offers multidisciplinary perspectives on groundbreaking presentations and sessions showcasing new and emerging tech in the vascular space.
I was able to sit down with Dan Rose, CEO of LimFlow SA, a medical device company bringing new hope to Critical Limb Ischemia patients, to discuss the upcoming reported outcomes of the 2 year PROMISE trial. This 2 year result reporting is critically important for the “leave no limb behind” mission.
At the conference, LimFlow will be announcing late-breaking 24-month data from the PROMISE I Study as well as other dedicated presentations on deep vein arterialization (DVA).
COVID had a big impact on the vascular care community as well as thrombotic complications that came out of the pandemic.
To learn more about the VIVA conference, visit https://vivaphysicians.org/viva-programming